HealthScout Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 
 
 Printer Friendly  Send to a Friend

New Test Diagnoses Anemia in Chronic Disease

Tool detects concentration of active hepcidin in the blood, researchers say


Related Encyclopedia
 border=
Anemia
Aneurysms
Angina Pectoris
Angiogram
More...

Related Healthscout Videos
 border=
Importance of Good Nutrition
Controlling Incontinence
Preventing Heart Disease the Easy Way
Lifestyle Changes for Heart Disease Prevention and Treatment
More...

Related Animations
 border=
Angioplasty
Coronary Bypass Surgery
Menopause
What is a Heart Attack?
More...

Related Drug Information
 border=
Accupril
Altace
Avapro
Cartia XT
More...

Related News Articles
 border=
Genes and Diabetes Increase Heart Problems
Heavy Traffic Can Be Heartbreaking
Transfusing Anemic Cancer Patients Boosts Clot Risk
The Ups and Downs of Alcohol
More...

TUESDAY, Aug. 5 (HealthDay News) -- A new tool for diagnosing anemia related to chronic illness and diseases of iron overload has been developed by U.S. researchers.

Both anemia and iron overload have various causes.

Text Continues Below



"It is hard to diagnose the anemia of chronic disease. Having an assay for hepcidin would make it much easier, and it would also help in diagnosing iron overload diseases," study senior author Jerry Kaplan, a professor of pathology and assistant vice president for research at the University of Utah Health Sciences, said in a university news release.

Hepcidin is a hormone produced in the liver. Iron balance in the body is regulated by the interaction between hepcidin and the iron transporting receptor ferroportin, according to background information in the news release. Hepcidin binds to ferroportin, resulting in decreased export of iron out of cells. An excess of hepcidin in the blood can cause anemia, while a deficiency of the hormone causes a build-up of iron that damages internal organs.

The University of Utah researchers and colleagues at the University of California, Los Angeles, identified the specific site where hepcidin binds to ferroportin. They then developed a rapid, sensitive test that measures the concentration of active hepcidin in the blood.

The test can detect variations in hepcidin levels due to mutations in genes known to affect hepcidin levels and mutations in genes involved in iron metabolism. The test can also measure hepcidin levels related to inflammation.

The researchers said the test would enable doctors to distinguish anemias and diseases of iron metabolism caused by abnormalities in hepcidin from those that have other causes.

The research was published in the August issue of Cell Metabolism.

More information

The U.S. National Heart, Lung, and Blood Institute has more about anemia.



-- Robert Preidt

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 8/5/2008

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates




SOURCE: University of Utah, news release, Aug. 5, 2008


Healthscout Search
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Resources
Healthscout News
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
Newsletter Subscription
News Archive
PR Newswire News Video Releases
Privacy Policy

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service